Antisense Therapeutics (ASX:ANP) has commenced dosing in a muscular dystrophy mouse model of Duchenne muscular dystrophy to assess the potential clinical utility of ATL1102 in combination with dystrophin restoration drugs. …
Antisense Therapeutics says dosing has commenced in combination study
September 12, 2022 Australian Biotech
Latest Video
New Stories
-
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech -
US and EU secure new trade agreement, but 'more to come' on pharmaceuticals
July 28, 2025 - - Latest News -
Leading stakeholders call for urgency on national genomics framework
July 28, 2025 - - Latest News -
Hepatitis Australia wants action as new analysis reveals many still missing cures
July 28, 2025 - - Latest News -
Ok for North Korea to have a say on our health responses, but not the US
July 28, 2025 - - Latest News